Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | ALPI | P09923 | 1/20 | 0.31 |
| ▸ | ALPG | P10696 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
| ▸ | YAP1 | P46937 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916835 | 0.89 | TMPRSS2 (0.32) | TMPRSS2EGLN2 | |
| SCHEMBL24916826 | 0.87 | TMPRSS2 (0.40) | TMPRSS2KMT2AKDM4EALDH1A1 | |
| SCHEMBL25912110 | 0.86 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL25912156 | 0.84 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL25912077 | 0.82 | TMPRSS2 (0.33) | MGLLTMPRSS2 | |
| SCHEMBL24916929 | 0.81 | TMPRSS2 (0.33) | MGLLTMPRSS2 | |
| SCHEMBL25608337 | 0.81 | MGLL (0.38) | MGLLTMPRSS2EGLN2 | |
| SCHEMBL25914014 | 0.77 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL25913461 | 0.76 | TMPRSS2 (0.34) | TMPRSS2ALDH1A1 | |
| SCHEMBL25914220 | 0.74 | TMPRSS2 (0.33) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024722-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | MGLL 1174/4885TMPRSS2 100/4885KMT2A 3232/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | MGLL 1174/4885TMPRSS2 100/4885KMT2A 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.